Plant Name: Euphorbia kansui
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.893E-08 | 3.748E-05 | BLM, CA1, CA12, CA2, CA3, CA4, CA6, CA7, CA9, TP53 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 3.681E-07 | 6.679E-04 | CYP1A2, CYP2A6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 4.435E-06 | 5.681E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0016712; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen | 4.300E-06 | 5.681E-03 | CYP1A2, CYP2A6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 8.864E-06 | 9.650E-03 | CYP1A2, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 6.329E-24 | 1.378E-19 | CA1, CA12, CA14, CA2, CA3, CA4, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 8.785E-19 | 9.564E-15 | CA1, CA12, CA14, CA2, CA3, CA4, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 4.542E-17 | 2.473E-13 | CA1, CA12, CA2, CA3, CA4, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 2.245E-23 | 2.200E-21 | CA12; CA1; CA3; CA2; CA4; CA7; CA6; CA9; CA14 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.028E-06 | 5.037E-05 | CYP2A6; CYP1A2; ALDH1A1; CYP3A4 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 7.552E-05 | 1.752E-03 | CYP2A6; CYP1A2; CYP3A4 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 8.936E-05 | 1.752E-03 | CYP2A6; CYP1A2; CYP3A4 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.263E-04 | 2.064E-03 | CYP2A6; CYP1A2; CYP3A4 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 6.101E-04 | 6.643E-03 | LMNA; TP53; NFKB1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.377E-05 | 4.498E-04 | CYP2A6; CYP1A2 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.263E-03 | 1.232E-02 | HPGD; TP53; NFKB1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.859E-03 | 1.875E-02 | CYP2A6; GAA; CYP1A2; ALDH1A1; CYP3A4; HSD17B10 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 5.493E-04 | 6.643E-03 | CYP1A2; CYP3A4 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 3.438E-04 | 4.814E-03 | CA2; CA4 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 2.825E-03 | 1.875E-02 | TP53; NFKB1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.383E-03 | 1.232E-02 | CYP2A6; CYP3A4 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 3.401E-03 | 1.875E-02 | MAPT; TP53; NFKB1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 2.909E-03 | 1.875E-02 | TP53; HIF1A |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.190E-03 | 1.788E-02 | CYP1A2; CYP3A4 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 3.443E-03 | 1.875E-02 | TP53; NFKB1 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 5.071E-03 | 2.485E-02 | TP53; NFKB1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 3.260E-03 | 1.875E-02 | CA2; CYP3A4 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 4.743E-03 | 2.447E-02 | TP53; NFKB1 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 5.640E-03 | 2.632E-02 | TP53; NFKB1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 6.733E-03 | 2.999E-02 | HIF1A; NFKB1 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.153E-02 | 4.036E-02 | HIF1A; TP53; NFKB1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 8.752E-03 | 3.543E-02 | TP53; HIF1A |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 9.039E-03 | 3.543E-02 | TP53; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 9.039E-03 | 3.543E-02 | TP53; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.101E-02 | 4.036E-02 | TP53; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 1.149E-02 | 4.036E-02 | TP53; NFKB1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.315E-02 | 4.443E-02 | TP53; NFKB1 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53 |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; CA9 |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; TP53; CA1; CA9; NFKB1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |